STING Agonist 11 | CAS#unknown | Activator

MedKoo Cat#: 208260 | Name: STING Agonist 11

Description:

WARNING: This product is for research use only, not for human or veterinary use.

STING Agonist 11 is a cytosolic DNA-sensing pathway that drives activation of type I interferons and other inflammatory cytokines, in the host immune response against tumors. The STING pathway is also increasingly understood to have other anti-tumor functions such as modulation of the vasculature and augmentation of adaptive immunity via the support of tertiary lymphoid structure development

Chemical Structure

STING Agonist 11

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 208260

Name: STING Agonist 11

CAS#: unknown

Chemical Formula: C17H12N4O4

Exact Mass: 336.0859

Molecular Weight: 336.31

Elemental Analysis: C, 60.71; H, 3.60; N, 16.66; O, 19.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

STINGAgonist11, STING-Agonist 11, STING-Agonist-11

IUPAC/Chemical Name

2-((Pyrazolo[1,5-a]pyrimidine-3-carboxamido)methyl)benzofuran-7-carboxylic acid

InChi Key

BICDHWPHEXMVAT-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H12N4O4/c22-16(13-9-20-21-6-2-5-18-15(13)21)19-8-11-7-10-3-1-4-12(17(23)24)14(10)25-11/h1-7,9H,8H2,(H,19,22)(H,23,24)

SMILES Code

OC(C1=CC=CC2=C1OC(CNC(C3=C4N(C=CC=N4)N=C3)=O)=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 336.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers (Basel). 2021 May 30;13(11):2695. doi: 10.3390/cancers13112695. PMID: 34070756; PMCID: PMC8198217. 2: Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, Xu Y, Nam J, Xu J, Shi X, Wei L, Lei YL, Moon JJ. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021 Nov;16(11):1260-1270. doi: 10.1038/s41565-021-00962-9. Epub 2021 Sep 30. PMID: 34594005; PMCID: PMC8595610. 3: Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019 Nov;20(11):657-674. doi: 10.1038/s41576-019-0151-1. Epub 2019 Jul 29. PMID: 31358977. 4: Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, Wei X, Guan Y, Liu J, Feng K, Jing M, Wang X, Liu YC, Mei Q, Han W, Jiang Z. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020 Nov;30(11):966-979. doi: 10.1038/s41422-020-00395-4. Epub 2020 Aug 24. PMID: 32839553; PMCID: PMC7785004. 5: Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. J Exp Med. 2021 Nov 1;218(11):e20200792. doi: 10.1084/jem.20200792. Epub 2021 Sep 24. PMID: 34559187; PMCID: PMC8480673. 6: Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7. PMID: 25959818; PMCID: PMC4440852. 7: Zhang Y, Lin S, Wang XY, Zhu G. Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Sep;11(5):e1559. doi: 10.1002/wnan.1559. Epub 2019 Jun 6. PMID: 31172659; PMCID: PMC7040494. 8: Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, Mai HQ, Chen QY, He J, Zhang XS, Zeng YX, Li J, Cui J. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 2019 Nov;26(11):2314-2328. doi: 10.1038/s41418-019-0302-0. Epub 2019 Feb 28. PMID: 30816302; PMCID: PMC6889506. 9: Heinz LX, Lee J, Kapoor U, Kartnig F, Sedlyarov V, Papakostas K, César- Razquin A, Essletzbichler P, Goldmann U, Stefanovic A, Bigenzahn JW, Scorzoni S, Pizzagalli MD, Bensimon A, Müller AC, King FJ, Li J, Girardi E, Mbow ML, Whitehurst CE, Rebsamen M, Superti-Furga G. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 2020 May;581(7808):316-322. doi: 10.1038/s41586-020-2282-0. Epub 2020 May 13. PMID: 32433612; PMCID: PMC7610944. 10: Zhang Y, Li M, Li L, Qian G, Wang Y, Chen Z, Liu J, Fang C, Huang F, Guo D, Zou Q, Chu Y, Yan D. β-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion. Nat Commun. 2020 Nov 26;11(1):6000. doi: 10.1038/s41467-020-19849-9. PMID: 33243993; PMCID: PMC7691508.